Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study / Lugaresi, A.; Durastanti, V.; Gasperini, C.; Lai, M.; Pozzilli, C.; Orefice, G.; Sotgiu, Stefano; Pucci, E.; Ardito, B.; Millefiorini, E.; the CoSa Study, Group. - In: CLINICAL NEUROPHARMACOLOGY. - ISSN 0362-5664. - 31:3(2008), pp. 167-172. [10.1097/wnf.0b013e3181571a8e]

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

SOTGIU, Stefano;
2008-01-01

2008
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study / Lugaresi, A.; Durastanti, V.; Gasperini, C.; Lai, M.; Pozzilli, C.; Orefice, G.; Sotgiu, Stefano; Pucci, E.; Ardito, B.; Millefiorini, E.; the CoSa Study, Group. - In: CLINICAL NEUROPHARMACOLOGY. - ISSN 0362-5664. - 31:3(2008), pp. 167-172. [10.1097/wnf.0b013e3181571a8e]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/44862
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? ND
social impact